These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 30879205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C, Caggiano V.
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G.
    Int J Cancer; 2019 Mar 15; 144(6):1251-1261. PubMed ID: 30367449
    [Abstract] [Full Text] [Related]

  • 5. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E.
    Arch Iran Med; 2016 Oct 15; 19(10):680-686. PubMed ID: 27743431
    [Abstract] [Full Text] [Related]

  • 6. Variation in breast cancer subtypes with age and race/ethnicity.
    Parise CA, Bauer KR, Caggiano V.
    Crit Rev Oncol Hematol; 2010 Oct 15; 76(1):44-52. PubMed ID: 19800812
    [Abstract] [Full Text] [Related]

  • 7. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    John EM, Koo J, Phipps AI, Longacre TA, Kurian AW, Ingles SA, Wu AH, Hines LM.
    Breast Cancer Res; 2024 May 31; 26(1):88. PubMed ID: 38822357
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G.
    Breast Cancer Res; 2017 Jan 23; 19(1):10. PubMed ID: 28114999
    [Abstract] [Full Text] [Related]

  • 12. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N, Hikichi M, Ushimado K, Sugioka A, Kiriyama Y, Kuroda M, Utsumi T.
    Clin Transl Oncol; 2017 Oct 23; 19(10):1232-1240. PubMed ID: 28409323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb 23; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 17. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L.
    BMC Cancer; 2013 May 04; 13():225. PubMed ID: 23642215
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K, Parise C, Caggiano V.
    BMC Cancer; 2010 May 21; 10():228. PubMed ID: 20492696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.